Researchers have engineered gut bacteria to help trigger immune responses against pancreatic tumors in animal models. Pancreatic cancer is especially challenging because tumors often create an immune-suppressing environment that prevents immune cells from effectively attacking them, making many immunotherapies less successful.

A team from the University of Chicago developed a strategy to deliver immune-boosting treatment directly into these resistant tumors by modifying Bifidobacterium longum, a naturally occurring probiotic gut bacterium. The engineered bacteria carried a therapeutic molecule called BifidoSumIL-2, designed to activate immune defenses within pancreatic tumors.

Figure 1. Engineered Bacteria Target Pancreatic Cancer

In animal studies, the engineered Bifidobacterium longum therapy stimulated cancer-fighting T cells and reduced pancreatic tumor growth. The treatment showed even greater effects when paired with existing approaches such as chemotherapy, radiation, and immunotherapy, indicating that it could potentially improve the response of pancreatic tumors to current therapies. Figure 1 shows Engineered Bacteria Target Pancreatic Cancer.

Researchers say the approach addresses a major challenge in pancreatic cancer treatment by finding a way to activate immune defenses inside tumors that are typically resistant to immune attack.

In animal studies, the engineered Bifidobacterium longum therapy stimulated cancer-fighting T cells and reduced pancreatic tumor growth. The treatment showed even greater effects when paired with existing approaches such as chemotherapy, radiation, and immunotherapy, indicating that it could potentially improve the response of pancreatic tumors to current therapies.

Researchers say the approach addresses a major challenge in pancreatic cancer treatment by finding a way to activate immune defenses inside tumors that are typically resistant to immune attack.

Engineering Precision Immune Therapy

Researchers developed BifidoSumIL-2, an engineered therapy that uses modified interleukin-2 (IL-2) to activate cancer-fighting immune cells while reducing the limitations of traditional IL-2 treatments. Standard IL-2 therapy can boost immune activity but may also cause severe side effects and activate regulatory T cells that weaken antitumor responses.

To improve safety and effectiveness, scientists created SumIL-2, a redesigned version of IL-2 that preferentially stimulates tumor-fighting T cells. By delivering this molecule through engineered Bifidobacterium longum, the treatment can concentrate immune activation directly inside pancreatic tumors.

The development of the therapy required collaboration across microbiology, synthetic biology, oncology, and immunology, combining expertise in bacteria engineering, cancer biology, and immune responses to create a targeted cancer treatment approach.

Bacteria Target Oxygen-Starved Tumor Regions

Bifidobacterium longum was chosen as a delivery vehicle because it naturally thrives in low-oxygen environments, a condition commonly found inside solid tumors such as pancreatic cancer. After being injected into the body, the bacteria are cleared from oxygen-rich healthy tissues but can survive and become active within oxygen-deprived tumor regions.

Inside tumors, the engineered bacteria act as tiny factories that produce and release SumIL-2 directly where it is needed, concentrating immune stimulation within the cancer while reducing effects on the rest of the body. Although Bifidobacterium has a strong safety profile and is widely used as a probiotic, modifying it for cancer therapy required overcoming challenges related to its slow growth, anaerobic nature, and limited genetic engineering tools.

Combination Therapy Enhances Tumor Control

In animal studies, BifidoSumIL-2 selectively accumulated in pancreatic tumors, activated immune defenses, and slowed cancer progression. The treatment reshaped the tumor environment by boosting CD8+ T cell activity, enabling stronger immune attacks against cancer cells. When combined with chemotherapy, radiation therapy, or anti-PD-L1 immunotherapy, the bacterial therapy produced greater tumor control and improved survival compared with individual treatments alone.

Although the approach has not yet reached human trials, researchers are investigating its long-term safety, durability of immune responses, and potential delivery methods [1]. The work represents a growing “bugs as drugs” strategy, where engineered probiotic bacteria serve as targeted delivery systems to bring therapies directly into hard-to-treat tumors while limiting effects on healthy tissues.

References:

1. https://scitechdaily.com/scientists-turn-gut-bacteria-into-pancreatic-cancer-fighters/

Cite this article:

Janani R (2026), Scientists Engineer Gut Bacteria to Fight Pancreatic Cancer, AnaTechMaz, pp. 829